SAEs in Late RA: Odds Ratios, Risk Ratios and Risk Difference for All Treatment Comparisons‐Random Effects Model
Treatment	Reference	OR (95% CrI)	RR (95% CrI)	RD % (95% Crl)
SD RITUX IV	MTX + PL	0.79 (0.09,4.27)	0.80 (0.09,3.70)	‐0.01 (‐0.06,0.13)
SD RITUX IV + MTX		2.02 (0.71,5.91)	1.90 (0.72,4.90)	0.05 (‐0.02,0.17)
SD INF IV + MTX		0.48 (0.16,1.42)	0.50 (0.17,1.39)	‐0.03 (‐0.06,0.02)
SD ANA SC + MTX		1.26 (0.39,4.26)	1.24 (0.41,3.65)	0.01 (‐0.04,0.14)
LD RITUX IV + MTX		2.67 (0.96,7.84)	2.43 (0.96,6.09)	0.08 (0.00,0.22)
HD INF IV + MTX		0.94 (0.35,2.57)	0.94 (0.36,2.37)	0.00 (‐0.04,0.07)
SD RITUX IV + MTX	SD RITUX IV	2.56 (0.50,21.54)	2.38 (0.55,18.75)	0.06 (‐0.07,0.17)
SD INF IV + MTX		0.61 (0.08,6.91)	0.62 (0.10,6.58)	‐0.02 (‐0.15,0.05)
SD ANA SC + MTX		1.61 (0.20,19.67)	1.56 (0.23,17.05)	0.02 (‐0.12,0.16)
LD RITUX IV + MTX		3.39 (0.68,28.39)	3.03 (0.72,23.75)	0.09 (‐0.04,0.22)
HD INF IV + MTX		1.20 (0.17,12.80)	1.19 (0.19,11.66)	0.01 (‐0.13,0.10)
SD INF IV + MTX	SD RITUX IV + MTX	0.24 (0.05,1.10)	0.26 (0.06,1.09)	‐0.08 (‐0.19,0.01)
SD ANA SC + MTX		0.63 (0.13,3.18)	0.65 (0.15,2.79)	‐0.04 (‐0.17,0.11)
LD RITUX IV + MTX		1.32 (0.54,3.31)	1.27 (0.58,2.84)	0.03 (‐0.07,0.14)
HD INF IV + MTX		0.47 (0.11,1.98)	0.50 (0.13,1.87)	‐0.05 (‐0.18,0.05)
SD ANA SC + MTX	SD INF IV + MTX	2.61 (0.54,13.70)	2.49 (0.56,11.58)	0.04 (‐0.03,0.17)
LD RITUX IV + MTX		5.58 (1.23,25.49)	4.91 (1.21,19.87)	0.11 (0.01,0.25)
HD INF IV + MTX		1.95 (0.65,5.91)	1.89 (0.67,5.46)	0.02 (‐0.02,0.09)
LD RITUX IV + MTX	SD ANA SC + MTX	2.13 (0.43,10.31)	1.97 (0.48,8.18)	0.07 (‐0.09,0.22)
HD INF IV + MTX		0.74 (0.15,3.47)	0.76 (0.18,3.20)	‐0.02 (‐0.15,0.08)
HD INF IV + MTX	LD RITUX IV + MTX	0.35 (0.08,1.48)	0.39 (0.10,1.42)	‐0.08 (‐0.23,0.03)
Random‐Effect Model	Residual Deviance	11.23 vs 12 data points
	Deviance Information Criteria	65.874
Fixed‐Effect Model	Residual Deviance	11.24 vs 12 data points
	Deviance Information Criteria	65.611
Note:
Total Patients	1390
Total Studies	4
2‐arm	1
3‐arm	2
4‐arm	1